Alight, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alight, Inc. on March 24, 2026. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the market price of the Company's Class A Common Stock, which averaged less than $1.00 per share over a consecutive 30 trading-day period ending March 20, 2026.
Material Changes and Events
- Delisting Notice: Alight received a written notice from the NYSE stating non-compliance with Section 802.01C of the Listed Company Manual due to the low average closing share price.
- Operational Impact: The notice does not affect ongoing business operations or SEC reporting requirements and has no immediate impact on the listing status.
Outlook, Management Commentary, and Risks
Management has responded to the NYSE with a commitment to cure the deficiency. The Company is considering available alternatives, including a reverse stock split, subject to stockholder approval at the next annual meeting. Alight has a six-month cure period to regain compliance. Compliance can be achieved if the stock closes at or above $1.00 and maintains a 30-day average of at least $1.00 on the last trading day of any calendar month within the cure period. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of regaining compliance.
Investor Verification Checklist
- Verify the current trading price and 30-day average of Alight's Class A Common Stock.
- Monitor announcements regarding the timing and terms of a potential reverse stock split.
- Review the Company's next annual meeting proxy statement for stockholder approval of the cure plan.
- Check subsequent filings for updates on the six-month cure period status.